LA JOLLA, Calif., March 5 /PRNewswire/ -- DermTech, a biotechnology company developing molecular diagnostics for the early detection of melanoma and other diseases, today announced that Allan C. Halpern, MD, has joined DermTech's Melanoma Advisory Board. Dr. Halpern is Chief of Dermatology at Memorial Sloan-Kettering Cancer Center and widely recognized as an expert in the early detection and management of melanoma in high-risk individuals.
"We are delighted and honored to welcome Dr. Halpern to our Melanoma Advisory Board," said George Schwartz, CEO, DermTech. "Dr. Halpern is a world leader in the area of melanoma and strategies for improved diagnosis and prevention of this disease that, if identified early, has an extremely high cure rate. DermTech will clearly benefit from his significant experience as we move toward clinical trials of our novel, non-invasive molecular diagnostic product for melanoma early detection."
"I am looking forward to working with the company and the outstanding panel of dermatologists and melanoma experts already on this advisory board," said Allan Halpern, MD. Other Melanoma Advisory Board members include: Boris Bastian, MD, David Polsky, MD, PhD, and Harold S. Rabinovitz, MD.
Allan Halpern, MD, is a board-certified internist and dermatologist. In
addition to his role as Chief of Dermatology at MSKCC, he is co-leader of
the Center's Melanoma Disease Management Team, which incorporates the
expertise of doctors in surgery, medical oncology, clinical immunology,
dermatology, pathology, and radiation oncology to diagnose and treat
melanoma. He pioneered the use of digital whole-body photography to assist
in the detection of changing moles in patients with dysplastic nevi (large,
irregular colored or shaped moles). Currently, his research is focused on
epidemiologic (population-based) studies with a subset of this research
devoted to the study of the genetic and environmental factors that
influence the development
'/>"/>
| SOURCE DermTech Copyright©2008 PR Newswire. All rights reserved |